https://ja.prisysbiotech.com/ 非 - 人間 霊長類 研究 プラットフォーム & クロ |プリシス バイオテクノロジー https://ja.prisysbiotech.com/uploads/39406/logo.png https://ja.prisysbiotech.com/nhp-pharmacology/ NHP薬理学 https://ja.prisysbiotech.com/uploads/39406/list/n20240227154733ebf63.jpg https://ja.prisysbiotech.com/safety-evaluation/ 安全性評価 https://ja.prisysbiotech.com/uploads/202339406/p202303211451568197109.jpg https://ja.prisysbiotech.com/translation-research/ 翻訳研究 https://ja.prisysbiotech.com/uploads/202339406/p202303211454114300368.jpg https://ja.prisysbiotech.com/biosafety-research/ バイオセーフティ研究 https://ja.prisysbiotech.com/uploads/202339406/p202303211456214933321.jpg https://ja.prisysbiotech.com/pk-pd-adme/ PK PD ADME https://ja.prisysbiotech.com/uploads/202339406/p202303211449418813566.jpg https://ja.prisysbiotech.com/nhp-pharmacology/non-human-primate.html Non-Human Primate (NHP) https://ja.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg Non-Human Primate (NHP) https://ja.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg https://ja.prisysbiotech.com/nhp-pharmacology/the-nhp-pharmacology-of-prisys.html The NHP Pharmacology Of Prisys https://ja.prisysbiotech.com/uploads/39406/page/small/the-nhp-pharmacology-of-prisysb465a.jpg The NHP Pharmacology Of Prisys https://ja.prisysbiotech.com/uploads/39406/page/the-nhp-pharmacology-of-prisysb465a.jpg https://ja.prisysbiotech.com/safety-evaluation/single-dose-repeated-dose-toxicity-testing.html Single-dose & Repeated Dose Toxicity Testing https://ja.prisysbiotech.com/uploads/39406/single-dose-repeated-dose-toxicity-testinga0b95.jpg Single-dose & Repeated Dose Toxicity Testing https://ja.prisysbiotech.com/uploads/39406/single-dose-repeated-dose-toxicity-testinga0b95.jpg https://ja.prisysbiotech.com/pk-pd-adme/toxicokinetics.html Toxicokinetics https://ja.prisysbiotech.com/uploads/39406/toxicokinetics70843.jpg Toxicokinetics https://ja.prisysbiotech.com/uploads/39406/toxicokinetics70843.jpg https://ja.prisysbiotech.com/nhp-pharmacology/what-is-a-nhp-study.html What Is A NHP Study https://ja.prisysbiotech.com/uploads/39406/page/small/what-is-a-nhp-study0fe0f.jpg What Is A NHP Study https://ja.prisysbiotech.com/uploads/39406/page/what-is-a-nhp-study0fe0f.jpg https://ja.prisysbiotech.com/biosafety-research/biosafetyresearch.html Biosafety Research https://ja.prisysbiotech.com/uploads/39406/page/small/biosafetyresearchcd745.jpg Biosafety Research https://ja.prisysbiotech.com/uploads/39406/page/biosafetyresearchcd745.jpg https://ja.prisysbiotech.com/nhp-pharmacology/nhp-non-alcoholic-steatohepatitis-nash-model.html NHP Non-Alcoholic Steatohepatitis (NASH) Model https://ja.prisysbiotech.com/uploads/202339406/small/nhp-non-alcoholic-steatohepatitis-nash-model7332a6f4-bc77-45be-bf2b-07178c46a62a.jpg NHP Non-Alcoholic Steatohepatitis (NASH) Model https://ja.prisysbiotech.com/uploads/202339406/nhp-non-alcoholic-steatohepatitis-nash-model7332a6f4-bc77-45be-bf2b-07178c46a62a.jpg https://ja.prisysbiotech.com/nhp-pharmacology/non-human-primate-model-renal-ischemia.html Non-Human Primate Model Renal Ischemia Reperfusion Injury (AKI To CKD Transition) https://ja.prisysbiotech.com/uploads/202339406/small/non-human-primate-model-renal-ischemia7ddb4a21-f360-4251-a51c-3cdb367eb3ad.jpg Non-Human Primate Model Renal Ischemia Reperfusion Injury (AKI To CKD Transition) https://ja.prisysbiotech.com/uploads/202339406/non-human-primate-model-renal-ischemia7ddb4a21-f360-4251-a51c-3cdb367eb3ad.jpg https://ja.prisysbiotech.com/nhp-pharmacology/coagulation-hemostasis-nonhuman-primates.html Coagulation/Hemostasis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/coagulation-hemostasis-nonhuman-primates63c5ab02-c0b4-4eb9-b521-9658b5017498.jpg Coagulation/Hemostasis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/coagulation-hemostasis-nonhuman-primates63c5ab02-c0b4-4eb9-b521-9658b5017498.jpg https://ja.prisysbiotech.com/translation-research/nhpresources.html NHP Resources https://ja.prisysbiotech.com/uploads/39406/page/small/nhpresources90325.jpg NHP Resources https://ja.prisysbiotech.com/uploads/39406/page/nhpresources90325.jpg https://ja.prisysbiotech.com/pk-pd-adme/pharmacokinetics.html Pharmacokinetics https://ja.prisysbiotech.com/uploads/39406/page/small/pharmacokineticsa44cd.jpg Pharmacokinetics https://ja.prisysbiotech.com/uploads/39406/page/pharmacokineticsa44cd.jpg https://ja.prisysbiotech.com/safety-evaluation/new-and-modified-applications.html New And Modified Applications https://ja.prisysbiotech.com/uploads/202339406/small/new-and-modified-applicationsab01b425-decb-46a1-90d1-e5fee60f1327.jpg New And Modified Applications https://ja.prisysbiotech.com/uploads/202339406/new-and-modified-applicationsab01b425-decb-46a1-90d1-e5fee60f1327.jpg https://ja.prisysbiotech.com/nhp-pharmacology/heart-failure-nonhuman-primates-disease-model.html Acute Myocardial Infarction/Heart Failure Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/acute-myocardial-infarction-heart-failure3d3bf8b7-5a0c-4f9d-8841-7f98a51cf834.jpg Acute Myocardial Infarction/Heart Failure Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/acute-myocardial-infarction-heart-failure3d3bf8b7-5a0c-4f9d-8841-7f98a51cf834.jpg https://ja.prisysbiotech.com/nhp-pharmacology/nhp-asthma-atopic-dermatitis-model.html NHP Asthma/atopic Dermatitis Model https://ja.prisysbiotech.com/uploads/202339406/small/nhp-asthma-atopic-dermatitis-model6bc15051-9b18-470b-a3ed-3a035fb26acc.jpg NHP Asthma/atopic Dermatitis Model https://ja.prisysbiotech.com/uploads/202339406/nhp-asthma-atopic-dermatitis-model6bc15051-9b18-470b-a3ed-3a035fb26acc.jpg https://ja.prisysbiotech.com/nhp-pharmacology/psoriasis-nonhuman-primates-disease-model.html Psoriasis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/small/psoriasis-nonhuman-primates-disease-model6e94c.jpg Psoriasis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/psoriasis-nonhuman-primates-disease-model6e94c.jpg https://ja.prisysbiotech.com/nhp-pharmacology/nhp-lung-fibrosis-model.html NHP Lung Fibrosis Model https://ja.prisysbiotech.com/uploads/39406/nhp-lung-fibrosis-model25cd4.jpg NHP Lung Fibrosis Model https://ja.prisysbiotech.com/uploads/39406/nhp-lung-fibrosis-model25cd4.jpg https://ja.prisysbiotech.com/nhp-pharmacology/delayed-type-hypersensitivity-dth-nonhuman.html Delayed-type Hypersensitivity (DTH) Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/small/delayed-type-hypersensitivity-dth-nonhuman90003.jpg Delayed-type Hypersensitivity (DTH) Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/delayed-type-hypersensitivity-dth-nonhuman90003.jpg https://ja.prisysbiotech.com/nhp-pharmacology/myopia-hyperopia-nhp-model.html Myopia Hyperopia Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/myopia-hyperopia-nhp-modela0553861-d7d5-4d4f-af65-68d25533d6ef.jpg Myopia Hyperopia Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/myopia-hyperopia-nhp-modela0553861-d7d5-4d4f-af65-68d25533d6ef.jpg https://ja.prisysbiotech.com/nhp-pharmacology/glaucoma-nonhuman-primates-disease-model.html Glaucoma Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/glaucoma-nonhuman-primates-disease-model092df254-f018-4636-a429-8344948a9978.jpg Glaucoma Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/glaucoma-nonhuman-primates-disease-model092df254-f018-4636-a429-8344948a9978.jpg https://ja.prisysbiotech.com/safety-evaluation/toxicology.html Toxicology https://ja.prisysbiotech.com/uploads/39406/toxicologycdb96.jpg Toxicology https://ja.prisysbiotech.com/uploads/39406/toxicologycdb96.jpg https://ja.prisysbiotech.com/nhp-pharmacology/multiple-sclerosis-nhp-model.html Multiple Sclerosis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/multiple-sclerosis-nhp-modelac9f75fb-b6ef-46d4-867c-1ad7b769490b.jpg Multiple Sclerosis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/multiple-sclerosis-nhp-modelac9f75fb-b6ef-46d4-867c-1ad7b769490b.jpg https://ja.prisysbiotech.com/nhp-pharmacology/hemophilia-a-nonhuman-primates-disease-model.html Hemophilia A Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/hemophilia-a-nonhuman-primates-disease-model4c747716-98c5-4ef0-a508-55e7790a46ff.jpg Hemophilia A Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/hemophilia-a-nonhuman-primates-disease-model4c747716-98c5-4ef0-a508-55e7790a46ff.jpg https://ja.prisysbiotech.com/safety-evaluation/dose-range-finding-test.html Dose Range Finding Test https://ja.prisysbiotech.com/uploads/39406/page/small/dose-range-finding-teste7c22.jpg Dose Range Finding Test https://ja.prisysbiotech.com/uploads/39406/page/dose-range-finding-teste7c22.jpg https://ja.prisysbiotech.com/nhp-pharmacology/tdar-nonhuman-primates-disease-model.html T Cell Dependent Antibody Response(TDAR) Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/small/tdar-nonhuman-primates-disease-modelae31c.jpg T Cell Dependent Antibody Response(TDAR) Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/tdar-nonhuman-primates-disease-modelae31c.jpg https://ja.prisysbiotech.com/nhp-pharmacology/embolism-nonhuman-primates-disease-model.html Pulmonary Artery Hypertension/Embolism Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/pulmonary-artery-hypertension-embolism9d266a3e-e0d5-46d2-85d6-aad09f286515.jpg Pulmonary Artery Hypertension/Embolism Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/pulmonary-artery-hypertension-embolism9d266a3e-e0d5-46d2-85d6-aad09f286515.jpg https://ja.prisysbiotech.com/nhp-pharmacology/rheumatoid-arthritis-nhp-model.html Rheumatoid Arthritis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/small/rheumatoid-arthritis-nhp-model438fa.jpg Rheumatoid Arthritis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/rheumatoid-arthritis-nhp-model438fa.jpg https://ja.prisysbiotech.com/nhp-pharmacology/amd-nonhuman-primates-disease-model.html AMD Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/amd-nonhuman-primates-disease-modelf663a012-d546-4fbb-8d78-834cea736255.jpg AMD Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/amd-nonhuman-primates-disease-modelf663a012-d546-4fbb-8d78-834cea736255.jpg https://ja.prisysbiotech.com/translation-research/translational-studies.html Translational Studies https://ja.prisysbiotech.com/uploads/202339406/small/translational-studiesd565144e-fcec-4437-afeb-42982ae7bab9.jpg Translational Studies https://ja.prisysbiotech.com/uploads/202339406/translational-studiesd565144e-fcec-4437-afeb-42982ae7bab9.jpg https://ja.prisysbiotech.com/nhp-pharmacology/nhp-chronic-obstructive-pulmonary-disease.html NHP Chronic Obstructive Pulmonary Disease (COPD) Model https://ja.prisysbiotech.com/uploads/202339406/small/nhp-chronic-obstructive-pulmonary-disease08000f1b-42f7-4c7d-9ba5-6f15c54993c9.jpg NHP Chronic Obstructive Pulmonary Disease (COPD) Model https://ja.prisysbiotech.com/uploads/202339406/nhp-chronic-obstructive-pulmonary-disease08000f1b-42f7-4c7d-9ba5-6f15c54993c9.jpg https://ja.prisysbiotech.com/nhp-pharmacology/uveitis-nonhuman-primates-disease-model.html Uveitis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/uveitis-nonhuman-primates-disease-model0ba7fdbf-75a4-42f7-8990-e9daa0c176b0.jpg Uveitis Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/uveitis-nonhuman-primates-disease-model0ba7fdbf-75a4-42f7-8990-e9daa0c176b0.jpg https://ja.prisysbiotech.com/nhp-pharmacology/epilepsy-nhp-model.html Epilepsy Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/small/epilepsy-nhp-model4f142.jpg Epilepsy Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/39406/page/epilepsy-nhp-model4f142.jpg https://ja.prisysbiotech.com/nhp-pharmacology/inflammatory-bowel-nhp-disease-model.html Inflammatory Bowel Disease Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/small/inflammatory-bowel-nhp-disease-modelf4c414ff-a224-4634-a994-b8ba7a18a488.jpg Inflammatory Bowel Disease Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/inflammatory-bowel-nhp-disease-modelf4c414ff-a224-4634-a994-b8ba7a18a488.jpg https://ja.prisysbiotech.com/pk-pd-adme/pharmacodynamics.html Pharmacodynamics https://ja.prisysbiotech.com/uploads/39406/pharmacodynamics620d3.jpg Pharmacodynamics https://ja.prisysbiotech.com/uploads/39406/pharmacodynamics620d3.jpg https://ja.prisysbiotech.com/safety-evaluation/immunotoxicity.html Immunotoxicity https://ja.prisysbiotech.com/uploads/202339406/small/immunotoxicitya758bdcf-a01c-4970-a80d-758e345ae77f.jpg Immunotoxicity https://ja.prisysbiotech.com/uploads/202339406/immunotoxicitya758bdcf-a01c-4970-a80d-758e345ae77f.jpg https://ja.prisysbiotech.com/nhp-pharmacology/nhp-monkey-disease-models.html NHP(monkey) Disease Models https://ja.prisysbiotech.com/uploads/39406/nhp-monkey-disease-models0f6a0.png NHP(monkey) Disease Models https://ja.prisysbiotech.com/uploads/39406/nhp-monkey-disease-models0f6a0.png https://ja.prisysbiotech.com/nhp-pharmacology/neuropathic-pain-nhp-model.html Neuropathic Pain Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/neuropathic-pain-nhp-modela385dae9-a466-42bb-9982-13db42e0581b.jpg Neuropathic Pain Nonhuman Primates Disease Model https://ja.prisysbiotech.com/uploads/202339406/neuropathic-pain-nhp-modela385dae9-a466-42bb-9982-13db42e0581b.jpg https://ja.prisysbiotech.com/pk-pd-adme/adme.html ADME https://ja.prisysbiotech.com/uploads/39406/adme55f5d.jpg ADME https://ja.prisysbiotech.com/uploads/39406/adme55f5d.jpg https://ja.prisysbiotech.com/nhp-pharmacology/mcao-nhp-model.html Middle Cerebral Artery Occlusion (MCAO) NHP Model Of Stoke & Brain Ischemia https://ja.prisysbiotech.com/uploads/202339406/mcao-nhp-model0cf8cbb0-48b5-473b-b725-fd749c9c69ca.jpg Middle Cerebral Artery Occlusion (MCAO) NHP Model Of Stoke & Brain Ischemia https://ja.prisysbiotech.com/uploads/202339406/mcao-nhp-model0cf8cbb0-48b5-473b-b725-fd749c9c69ca.jpg https://ja.prisysbiotech.com/clearpoint/clearpoint-navigation-for-cns-research.html ClearPoint Navigation For CNS Research https://ja.prisysbiotech.com/uploads/39406/page/small/clearpoint-navigation-for-cns-researchf4cb9.jpg ClearPoint Navigation For CNS Research https://ja.prisysbiotech.com/uploads/39406/page/clearpoint-navigation-for-cns-researchf4cb9.jpg https://ja.prisysbiotech.com/translation-research/ai-based-nhp-behavior-analysis-system.html AI-based NHP Behavior Analysis System https://ja.prisysbiotech.com/uploads/39406/ai-based-nhp-behavior-analysis-systema5d80.png AI-based NHP Behavior Analysis System https://ja.prisysbiotech.com/uploads/39406/ai-based-nhp-behavior-analysis-systema5d80.png https://ja.prisysbiotech.com/nhp-pharmacology/parkinson-s-disease-model.html Parkinson's Disease Model https://ja.prisysbiotech.com/uploads/39406/page/small/parkinson-s-disease-model9ce85.jpg Parkinson's Disease Model https://ja.prisysbiotech.com/uploads/39406/page/parkinson-s-disease-model9ce85.jpg https://ja.prisysbiotech.com/translation-research/clinical-imaging.html 臨床画像処理 https://ja.prisysbiotech.com/uploads/39406/clinical-imaging585d0.jpg 臨床画像処理 https://ja.prisysbiotech.com/uploads/39406/clinical-imaging585d0.jpg Clinical Imaging https://ja.prisysbiotech.com/uploads/202439406/small/clinical-imagingb514bd15-133f-4e9b-a75a-0e1cbbc1f4f0.jpg Clinical Imaging https://ja.prisysbiotech.com/uploads/202439406/clinical-imagingb514bd15-133f-4e9b-a75a-0e1cbbc1f4f0.jpg Clinical Imaging https://ja.prisysbiotech.com/uploads/202439406/small/clinical-imagingb9ae57aa-6754-41ce-822c-46e3f1c3d84a.jpg Clinical Imaging https://ja.prisysbiotech.com/uploads/202439406/clinical-imagingb9ae57aa-6754-41ce-822c-46e3f1c3d84a.jpg Clinical Imaging https://ja.prisysbiotech.com/uploads/202439406/small/clinical-imaginga1e6f856-06fb-4365-aa1c-53949acb37af.jpg Clinical Imaging https://ja.prisysbiotech.com/uploads/202439406/clinical-imaginga1e6f856-06fb-4365-aa1c-53949acb37af.jpg Clinical Imaging https://ja.prisysbiotech.com/uploads/202439406/small/clinical-imagingb127b97f-7b00-4335-b905-64e36f57247d.jpg Clinical Imaging https://ja.prisysbiotech.com/uploads/202439406/clinical-imagingb127b97f-7b00-4335-b905-64e36f57247d.jpg https://ja.prisysbiotech.com/nhp-pharmacology/immunosuppression-model.html Immunosuppression Model https://ja.prisysbiotech.com/uploads/39406/page/small/immunosuppression-model9e95e.jpg Immunosuppression Model https://ja.prisysbiotech.com/uploads/39406/page/immunosuppression-model9e95e.jpg https://ja.prisysbiotech.com/nhp-pharmacology/a-v-shunt-model.html A-V Shunt Model https://ja.prisysbiotech.com/uploads/39406/a-v-shunt-modelef93d.jpg A-V Shunt Model https://ja.prisysbiotech.com/uploads/39406/a-v-shunt-modelef93d.jpg https://ja.prisysbiotech.com/nhp-pharmacology/hyperlipoidemia-model.html Hyperlipoidemia Model https://ja.prisysbiotech.com/uploads/39406/hyperlipoidemia-modeldc1b0.png Hyperlipoidemia Model https://ja.prisysbiotech.com/uploads/39406/hyperlipoidemia-modeldc1b0.png https://ja.prisysbiotech.com/nhp-pharmacology/endometriosis-model.html Endometriosis Model https://ja.prisysbiotech.com/uploads/39406/endometriosis-modeldd994.png Endometriosis Model https://ja.prisysbiotech.com/uploads/39406/endometriosis-modeldd994.png https://ja.prisysbiotech.com/nhp-pharmacology/type-1-diabetes-mellitus-model.html Type 1 Diabetes Mellitus Model https://ja.prisysbiotech.com/uploads/39406/type-1-diabetes-mellitus-modelbc16f.png Type 1 Diabetes Mellitus Model https://ja.prisysbiotech.com/uploads/39406/type-1-diabetes-mellitus-modelbc16f.png https://ja.prisysbiotech.com/nhp-pharmacology/renal-fibrosis-model.html Renal Fibrosis Model https://ja.prisysbiotech.com/uploads/39406/renal-fibrosis-modelb87a4.jpg Renal Fibrosis Model https://ja.prisysbiotech.com/uploads/39406/renal-fibrosis-modelb87a4.jpg https://ja.prisysbiotech.com/nhp-pharmacology/type-2-diabetes-mellitus-model.html 2 型糖尿病モデル https://ja.prisysbiotech.com/uploads/39406/type-2-diabetes-mellitus-model5981d.png 2 型糖尿病モデル https://ja.prisysbiotech.com/uploads/39406/type-2-diabetes-mellitus-model5981d.png https://ja.prisysbiotech.com/clearpoint/convection-enhanced-delivery-ced-technology.html Convection-Enhanced Delivery (CED) Technology https://ja.prisysbiotech.com/uploads/39406/convection-enhanced-delivery-ced-technology7e74b.png Convection-Enhanced Delivery (CED) Technology https://ja.prisysbiotech.com/uploads/39406/convection-enhanced-delivery-ced-technology7e74b.png https://ja.prisysbiotech.com/clearpoint/nhp-neuroscience.html NHP Neuroscience https://ja.prisysbiotech.com/uploads/39406/nhp-neuroscience94a5c.jpg NHP Neuroscience https://ja.prisysbiotech.com/uploads/39406/nhp-neuroscience94a5c.jpg https://ja.prisysbiotech.com/nhp-pharmacology/atopic-dermatitis-nhp-model.html Atopic Dermatitis NHP Model https://ja.prisysbiotech.com/uploads/39406/atopic-dermatitis-nhp-model0fc1f.jpg Atopic Dermatitis NHP Model https://ja.prisysbiotech.com/uploads/39406/atopic-dermatitis-nhp-model0fc1f.jpg https://ja.prisysbiotech.com/nhp-pharmacology/pruritus-nhp-model.html Pruritus NHP Model https://ja.prisysbiotech.com/uploads/39406/pruritus-nhp-modelfcbdb.jpg Pruritus NHP Model https://ja.prisysbiotech.com/uploads/39406/pruritus-nhp-modelfcbdb.jpg https://ja.prisysbiotech.com/translation-research/targeted-organ-drug-delivery-platform-in-nhp.html Targeted Organ Drug Delivery Platform in NHP https://ja.prisysbiotech.com/uploads/39406/targeted-organ-drug-delivery-platform-in-nhpe13f9.png Targeted Organ Drug Delivery Platform in NHP https://ja.prisysbiotech.com/uploads/39406/targeted-organ-drug-delivery-platform-in-nhpe13f9.png https://ja.prisysbiotech.com/nhp-pharmacology/inflammatory-bowel-disease-ibd-nhp-model.html Inflammatory Bowel Disease IBD NHP Model https://ja.prisysbiotech.com/uploads/39406/small/inflammatory-bowel-disease-ibd-nhp-model048b6.png Inflammatory Bowel Disease IBD NHP Model https://ja.prisysbiotech.com/uploads/39406/inflammatory-bowel-disease-ibd-nhp-model048b6.png https://ja.prisysbiotech.com/nhp-pharmacology/aav-synuclein-overexpression-nhp-model.html AAV-α-Synuclein Overexpression NHP Model https://ja.prisysbiotech.com/uploads/39406/small/aav-synuclein-overexpression-nhp-model93460.jpg AAV-α-Synuclein Overexpression NHP Model https://ja.prisysbiotech.com/uploads/39406/aav-synuclein-overexpression-nhp-model93460.jpg https://ja.prisysbiotech.com/nhp-pharmacology/heart-failure-nhp-model.html Heart Failure NHP Model https://ja.prisysbiotech.com/uploads/39406/small/heart-failure-nhp-model8c759.jpg Heart Failure NHP Model https://ja.prisysbiotech.com/uploads/39406/heart-failure-nhp-model8c759.jpg https://ja.prisysbiotech.com/nhp-pharmacology/acute-lung-inflammation-ali-nhp-model.html Acute Lung Inflammation (ALI) NHP Model https://ja.prisysbiotech.com/uploads/39406/page/small/acute-lung-inflammation-ali-nhp-modelcce6e.png Acute Lung Inflammation (ALI) NHP Model https://ja.prisysbiotech.com/uploads/39406/page/acute-lung-inflammation-ali-nhp-modelcce6e.png https://ja.prisysbiotech.com/pk-pd-adme/nose-to-brain-drug-delivery.html Nose-to-Brain Drug Delivery https://ja.prisysbiotech.com/uploads/39406/small/nose-to-brain-drug-delivery15a9e.jpg Nose-to-Brain Drug Delivery https://ja.prisysbiotech.com/uploads/39406/nose-to-brain-drug-delivery15a9e.jpg https://ja.prisysbiotech.com/nhp-pharmacology/acute-hemorrhagic-shock-model-nhp-model.html Acute Hemorrhagic Shock Model NHP Model https://ja.prisysbiotech.com/uploads/39406/small/acute-hemorrhagic-shock-model-nhp-model5b827.png Acute Hemorrhagic Shock Model NHP Model https://ja.prisysbiotech.com/uploads/39406/acute-hemorrhagic-shock-model-nhp-model5b827.png https://ja.prisysbiotech.com/nhp-pharmacology/retinitis-pigmentosa-rp-nhp-model.html Retinitis Pigmentosa (RP) NHP Model https://ja.prisysbiotech.com/uploads/39406/small/retinitis-pigmentosa-rp-nhp-model49f0f.png Retinitis Pigmentosa (RP) NHP Model https://ja.prisysbiotech.com/uploads/39406/retinitis-pigmentosa-rp-nhp-model49f0f.png https://ja.prisysbiotech.com/nhp-pharmacology/liver-fibrosis-model.html Liver Fibrosis Model https://ja.prisysbiotech.com/uploads/39406/small/liver-fibrosis-modelc2688.png Liver Fibrosis Model https://ja.prisysbiotech.com/uploads/39406/liver-fibrosis-modelc2688.png https://ja.prisysbiotech.com/news/2025-recap-how-prisys-is-redefining-translati-17724106676134912.html 2025 年の要約: Prisys が NHP 研究におけるトランスレーショナル信頼性をどのように再定義しているか https://ja.prisysbiotech.com/uploads/39406/news/n20260115105444c1b0c.jpg https://ja.prisysbiotech.com/news/nhp-based-pharmacology-and-pharmacodynamic-17551257318122496.html NHPベースの薬理学と薬力学的サービス| Prisys Biotech https://ja.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg https://ja.prisysbiotech.com/news/meet-prisys-biotech-at-upcoming-eu-roadshow-17528772678001664.html 今後のEUロードショーでPrisys Biotechに会いましょう：2025年9月 https://ja.prisysbiotech.com/uploads/39406/news/n2025082013335410dba.jpg https://ja.prisysbiotech.com/news/prisys-biotech-2025-mid-year-review-17439718980051968.html Prisys Biotech - 2025年の中年レビュー https://ja.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg https://ja.prisysbiotech.com/news/meet-prisys-in-2025-us-roadshow-17244147024897024.html 2025年3月に開催される米国の路上でPrisysに会いましょう https://ja.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg https://ja.prisysbiotech.com/news/prisys-annual-report-2024-advancing-nhp-model-84008491.html PRISYS 年次報告書 2024: NHP モデルと前臨床研究の進歩 https://ja.prisysbiotech.com/uploads/39406/news/n20241204135917ca94f.jpg https://ja.prisysbiotech.com/news/prisys-biotech-2024-q2-newsletter-77698392.html Prisys Biotech 2024 Q2 ニュースレター - PRISYS 交差反応性モデルによる CNS 治療の前臨床研究開発の強化 https://ja.prisysbiotech.com/uploads/39406/news/n20240520124055bc2de.png https://ja.prisysbiotech.com/news/rtimri-for-parkinsons-disease-81121001.html パーキンソン病の標的治療：リアルタイム MRI 誘導幹細胞移植の画期的進歩 https://ja.prisysbiotech.com/uploads/39406/news/n202409061001122b75a.jpg https://ja.prisysbiotech.com/news/emotional-memory-chronic-pain-nhp-models-17724116660970496.html 痛みが記憶になるとき: 慢性痛の感情的要因と NHP モデルの利点 |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n2026012713131077473.jpg https://ja.prisysbiotech.com/news/multi-endpoint-pain-assessment-the-future-17724116562158592.html マルチエンドポイント疼痛評価: 鎮痛薬開発の未来 https://ja.prisysbiotech.com/uploads/39406/news/n20260123153636bce28.jpg https://ja.prisysbiotech.com/news/analgesics-fail-in-preclinical-measure-pain-17724116589945856.html なぜこれほど多くの鎮痛薬が前臨床試験で失敗するのでしょうか?答えは痛みの測定方法にあります https://ja.prisysbiotech.com/uploads/39406/news/n20260120155944a4ef1.jpg https://ja.prisysbiotech.com/news/blood-sampling-time-point-in-pharmacokinetic-17724106827097088.html 薬物動態 (PK) 研究における血液サンプリング時点の設計 |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n2026011316592151314.jpg https://ja.prisysbiotech.com/news/pk-statistical-analysis-nca-parameters-guide-17724106836845568.html PK 統計: ノンコンパートメント分析 (NCA) パラメータと前臨床応用- https://ja.prisysbiotech.com/uploads/39406/news/n20260109161837141c9.jpg https://ja.prisysbiotech.com/news/non-human-primate-models-are-critical-cns-17724106856801280.html なぜ非ヒト霊長類モデルが CNS オリゴヌクレオチド治療に重要なのか{0} https://ja.prisysbiotech.com/uploads/39406/news/n20260106130909b5b92.jpg https://ja.prisysbiotech.com/news/uric-acid-metabolism-in-humans-vs-monkeys-17724106742014976.html ヒトとサルの尿酸代謝：医薬品開発へのトランスレーショナルな意味 https://ja.prisysbiotech.com/uploads/39406/news/2026010416213306463.jpg https://ja.prisysbiotech.com/news/non-human-primate-mash-associated-liver-fibros-17724106567132160.html 非-ヒト霊長類 MASH- 関連肝線維症モデル |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/p20251226155519da3af.png https://ja.prisysbiotech.com/news/imri-guided-brain-drug-delivery-17724106637075456.html NHP 研究における正確なターゲティングに IMRI-誘導脳薬物送達が不可欠な理由 https://ja.prisysbiotech.com/uploads/39406/news/n202512231619222564f.png https://ja.prisysbiotech.com/news/ai-driven-markerless-3d-behavioral-analysis-17674141099877376.html AI- 駆動のマーカーレス NHP 3D 行動分析システム |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n202512181608129079f.jpg https://ja.prisysbiotech.com/news/lps-induced-acute-lung-inflammation-ali-nhp-17674141225575424.html LPS-誘発性急性肺炎症 (ALI) NHP モデル |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n202512161502375ccdb.jpg https://ja.prisysbiotech.com/news/hdm-seb-induced-atopic-dermatitis-atd-model-17674141133480960.html HDM+SEB-カニクイザルにおけるアトピー性皮膚炎（AtD）モデル https://ja.prisysbiotech.com/uploads/39406/news/n20251212144449750c1.jpg https://ja.prisysbiotech.com/news/one-to-multi-compartment-pk-models-17674141321700352.html 1- からマルチ-コンパートメント PK モデルの説明|NHP 薬物動態学 |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n20251208140839d8db0.jpg https://ja.prisysbiotech.com/news/how-to-choose-a-reliable-preclinical-cro-key-17674141157516288.html 信頼できる前臨床 CRO を選ぶ方法 |バイオテクノロジー企業の重要な基準 |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n20251204133731f364a.jpg https://ja.prisysbiotech.com/news/translational-car-t-evaluation-in-vitro-17674141078627328.html トランスレーショナル CAR-T 評価: In Vitro の専門知識と NHP 研究サポート — Prisys Biotech https://ja.prisysbiotech.com/uploads/39406/news/n202512011123451e873.png https://ja.prisysbiotech.com/news/cns-drug-candidates-in-preclinical-study-17674141114491904.html なぜ中枢神経系治療薬候補の90%以上が臨床試験で失敗するのでしょうか? https://ja.prisysbiotech.com/uploads/39406/news/n202511281410270841e.png https://ja.prisysbiotech.com/news/parkinsons-disease-preclinical-models-17674141140280320.html パーキンソン病の前臨床モデル: 神経毒、遺伝子、および NHP モデルの選択ガイド |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n2025112415472074828.png https://ja.prisysbiotech.com/news/high-precision-drug-delivery-and-ai-driven-nhp-17674141145408512.html 高-精度のドラッグデリバリーと AI{1}} 主導の NHP トランスレーショナル プラットフォーム https://ja.prisysbiotech.com/uploads/39406/news/n2025112108401436404.jpg https://ja.prisysbiotech.com/news/th17-driven-nhp-immunology-models-17625013912871936.html Th17 駆動 NHP 免疫モデル|Prisys Biotech におけるトランスレーショナル自己免疫研究 https://ja.prisysbiotech.com/uploads/39406/news/n20251117110751844f3.png https://ja.prisysbiotech.com/news/ai-based-nhp-behavioratlas-system-3d-behavi-17625015521993728.html AI- ベースの NHP BehaviorAtlas® システム|3D行動分析プラットフォーム |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n20251114162428314a9.png https://ja.prisysbiotech.com/news/rfp-template-for-nhp-studies-17625013947507712.html NHP 研究用の RFP テンプレート |前臨床研究の効率を加速する https://ja.prisysbiotech.com/uploads/39406/news/n2025111015483953c4b.jpg https://ja.prisysbiotech.com/news/cold-allodynia-pain-model-in-cynomolgus-monkey-17625013799609344.html カニクイザルにおける寒冷異痛症疼痛モデル |プリシス・バイオテクノロジーズ https://ja.prisysbiotech.com/uploads/39406/news/n20251107160515acddb.jpg https://ja.prisysbiotech.com/news/mri-guided-intracerebral-drug-delivery-17625013970166784.html MRI-誘導型脳内薬物送達プラットフォーム|Prisys Biotech CNS 研究 https://ja.prisysbiotech.com/uploads/39406/news/n2025110514460235db1.jpg https://ja.prisysbiotech.com/news/nhp-respiratory-disease-models-and-airway-drug-17625014052709376.html NHP 呼吸器疾患モデルと気道薬物送達プラットフォーム |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n20251028164336adaf3.png https://ja.prisysbiotech.com/news/nhp-renal-biopsy-17625014095930368.html NHP 腎生検プラットフォームと腎臓疾患モデル |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n20251022172158e338d.jpg https://ja.prisysbiotech.com/news/pk-study-targeted-drug-delivery-17625014114362368.html PK 研究と標的薬物送達 |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n202510171638300dafe.jpg https://ja.prisysbiotech.com/news/nhp-ai-based-behavioral-analysis-17625014887998464.html Prisys Biotechnologies の NHP 研究および AI{0}} ベースの行動分析プラットフォーム https://ja.prisysbiotech.com/uploads/39406/news/n2025101517485012ee9.jpg https://ja.prisysbiotech.com/news/nasal-to-brain-n2b-delivery-technology-for-c-17625013734040576.html CNS 研究向けの鼻-から-への（N2B）送達テクノロジー |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n20251011133522c7c7b.jpg https://ja.prisysbiotech.com/news/shr-2004-a-breakthrough-in-vte-prevention-for-17625013646271488.html SHR-2004: 卵巣がん患者の VTE 予防における画期的な進歩 – Prisys Biotech による成功事例 https://ja.prisysbiotech.com/uploads/39406/news/n2025101011280623985.jpg https://ja.prisysbiotech.com/news/cynomolgus-rhesus-monkey-models-prisys-bio-17537834598867968.html Cynomolgus＆Rhesusモンキーモデル| Prisys Biotech Preclinical Cro https://ja.prisysbiotech.com/uploads/39406/news/n202509191421539fa9b.jpg https://ja.prisysbiotech.com/news/idiopathic-pulmonary-fibrosis-ipf-nhp-model-17528772539491328.html 特発性肺線維症（IPF）NHPモデル| Prisys Biotech Preclinical Cro https://ja.prisysbiotech.com/uploads/39406/news/n20250912151948fd2c4.jpg https://ja.prisysbiotech.com/news/cynomolgus-monkey-biodistribution-study-17528772666139648.html Cynomolgusモンキーの生体内分布研究| Prisys Biotech Preclinical Cro https://ja.prisysbiotech.com/uploads/39406/news/n202509091635226f118.jpg https://ja.prisysbiotech.com/news/nhp-models-for-hematology-and-stroke-17528772678018048.html 血液学および脳卒中研究のためのPrisys Biotech NHPモデル https://ja.prisysbiotech.com/uploads/39406/news/n20250903101944cac91.jpg https://ja.prisysbiotech.com/news/the-importance-of-administration-volume-17528772563313664.html 前臨床研究における投与量の重要性| Prisys Biotech https://ja.prisysbiotech.com/uploads/39406/news/n202508261427201a2af.gif https://ja.prisysbiotech.com/news/brain-targeted-drug-delivery-17528751041586176.html 脳-標的薬物送達| Prisys Biotech前臨床NHP研究 https://ja.prisysbiotech.com/uploads/39406/news/n202508221539309f4a5.jpg https://ja.prisysbiotech.com/news/adc-drug-development-translational-pk-pd-fra-17528772896154624.html ADCドラッグ開発|前臨床NHP研究における翻訳PK/PDフレームワーク https://ja.prisysbiotech.com/uploads/39406/news/n2025081814020269ffa.jpg https://ja.prisysbiotech.com/news/nhp-pain-models-for-translational-drug-discove-17493738266010624.html 翻訳される創薬のためのNHP痛モデル| Prisys Biotech https://ja.prisysbiotech.com/uploads/39406/news/n20250813095806db594.jpg https://ja.prisysbiotech.com/news/serum-vs-plasma-choosing-the-optimal-matrix-17493738225673216.html 血清対プラズマ：前臨床生体分析のための最適なマトリックスを選択します https://ja.prisysbiotech.com/uploads/39406/news/n20250805095551af23f.jpg https://ja.prisysbiotech.com/news/preclinical-dosing-guidelines-iv-po-volume-17493738228491264.html 前臨床投与ガイドライン：NHPおよびその他の種の正確なPKのIV＆POボリューム、pH、および浸透圧力 https://ja.prisysbiotech.com/uploads/39406/news/n20250731153850aa43a.jpg https://ja.prisysbiotech.com/news/nhp-copd-model-17493738346456064.html PrisysによるトップCOPD研究モデルと呼吸プラットフォームの卓越性 https://ja.prisysbiotech.com/uploads/39406/news/n20250730125053bd455.jpg https://ja.prisysbiotech.com/news/nhp-acute-hemorrhage-model-17493738120979456.html NHP急性出血モデル：新規血液学薬の発達を加速するための重要なツール https://ja.prisysbiotech.com/uploads/39406/news/n20250722163908bd854.png https://ja.prisysbiotech.com/news/pruritus-research-il-31-nhp-itch-model-17493738167395328.html Pruritus Research：Prisys BiotechのAnti-Sitch療法を評価するためのIL-31誘導NHPモデル https://ja.prisysbiotech.com/uploads/39406/news/n202504011023488ec4a.png https://ja.prisysbiotech.com/news/a-guide-to-anti-drug-antibody-ada-assessment-17439718978446336.html 抗薬物抗体（ADA）評価のガイド https://ja.prisysbiotech.com/uploads/39406/news/n2025071015011851653.jpg https://ja.prisysbiotech.com/news/respiratory-therapies-prisys-biotech-s-integr-17439719029285888.html 呼吸療法：Prisys Biotechの前臨床研究のための統合NHPプラットフォーム https://ja.prisysbiotech.com/uploads/39406/news/n202507080951326501f.gif https://ja.prisysbiotech.com/news/nhp-pain-models-accelerating-analgesic-drug-d-17439719075013632.html NHPの痛みモデル：Prisys Biotechでの鎮痛薬の促進薬の発達の加速 https://ja.prisysbiotech.com/uploads/39406/news/p20250704135241befde.png https://ja.prisysbiotech.com/news/nhp-model-platforms-to-support-drug-developmen-17439719199482880.html 複雑な疾患の医薬品開発をサポートするNHPモデルプラットフォーム https://ja.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg https://ja.prisysbiotech.com/news/key-considerations-for-dosing-volume-17439757098214400.html 動物モデルの投与量、pH、および製剤に関する重要な考慮事項 https://ja.prisysbiotech.com/uploads/39406/news/n202506260936191360e.png https://ja.prisysbiotech.com/news/engineered-exosomes-revolutionizing-drug-deli-17439719015130112.html エンジニアリングされたエキソソーム：CNS障害のための薬物送達の革新 - Prisysバイオテクノロジーからの前臨床洞察 https://ja.prisysbiotech.com/uploads/39406/news/n20250617131838d8cea.jpg https://ja.prisysbiotech.com/news/guiding-principles-for-animal-species-selectio-17439718921249792.html 核酸薬物毒物学研究における動物種選択の指針 https://ja.prisysbiotech.com/uploads/39406/news/n202506131705069d4cc.jpg https://ja.prisysbiotech.com/news/prisys-biotech-s-advanced-dsa-and-imri-for-hem-17439719190701056.html Prisys Biotechの高度なDSAと血管疾患および腎疾患の研究のためのIMRI https://ja.prisysbiotech.com/uploads/39406/news/n20250610100231b6146.jpg https://ja.prisysbiotech.com/news/cynomolgus-monkey-pain-models-17439719231169536.html Cynomolgus Monkey Pain Models：画期的なイオンチャネル治療のためのトランスレーショナルリサーチの動力 https://ja.prisysbiotech.com/uploads/39406/news/n20250605125053411da.jpg https://ja.prisysbiotech.com/news/advancing-atopic-dermatitis-research-prisys-b-17439719208739840.html アトピー性皮膚炎研究の進歩：Prisys Biotechの非人間霊長類（NHP）モデル https://ja.prisysbiotech.com/uploads/39406/news/n20250530142432192c3.jpg https://ja.prisysbiotech.com/news/prisys-biotech-s-nhp-atopic-dermatitis-model-f-17439718965339136.html Prisys BiotechのNHP抗prulitic薬物開発のための皮膚皮膚炎モデル https://ja.prisysbiotech.com/uploads/39406/news/p20250527155048d3f8c.png https://ja.prisysbiotech.com/news/designing-animal-studies-key-considerations-f-17380877979460608.html 動物研究の設計：前臨床研究の成功のための重要な考慮事項 https://ja.prisysbiotech.com/uploads/39406/news/n2025052317011698995.jpg https://ja.prisysbiotech.com/news/atopic-dermatitis-how-cynomolgus-monkey-model-17374316800238592.html アトピー性皮膚炎：Cynomolgusモンキーモデルがどのように精密治療を進める方法 https://ja.prisysbiotech.com/uploads/39406/news/n2025052012503626be2.jpg https://ja.prisysbiotech.com/news/asthma-research-why-non-human-primate-models-17374316749284352.html 喘息の研究：なぜ人間以外の霊長類モデルが新しい医薬品開発にとって極めて重要であるのか https://ja.prisysbiotech.com/uploads/39406/news/n20250512174400b2bec.jpg https://ja.prisysbiotech.com/news/aso-pharmacokinetics-absorption-17374316669559808.html アンチセンスオリゴヌクレオチド（ASO）薬物動態の理解：吸収と分布の重要な要因 https://ja.prisysbiotech.com/uploads/39406/news/n202505081658273697e.jpg https://ja.prisysbiotech.com/news/nhp-inhalation-studies-for-biologics-prisys-17374317113615360.html 生物学のためのNHP吸入研究：Prisysの専門的な前臨床CROサービス https://ja.prisysbiotech.com/uploads/39406/news/n2025043015244899508.jpg https://ja.prisysbiotech.com/news/advanced-preclinical-inhalation-studies-techn-17374316772664320.html 高度な前臨床吸入研究：Prisys Biotechの技術的能力と専門知識 https://ja.prisysbiotech.com/uploads/39406/news/n202504291646054725d.jpg https://ja.prisysbiotech.com/news/pharmacokinetics-pk-key-parameters-17380939354956800.html 薬物動態の理解（PK）：医薬品開発における重要なパラメーターとアプリケーション https://ja.prisysbiotech.com/uploads/39406/news/n2025042511302920eb4.webp https://ja.prisysbiotech.com/news/intracerebroventricular-icv-injection-17374316923741184.html 脳室内（ICV）注入：前臨床研究のための精密CNS送達 https://ja.prisysbiotech.com/uploads/39406/news/n2025042210212390d49.jpg https://ja.prisysbiotech.com/news/intracerebral-icm-injection-precision-targe-17374316758590464.html 脳内（ICM）注射：CNS治療薬の精密ターゲティング - 前臨床考慮事項 https://ja.prisysbiotech.com/uploads/39406/news/n202504180938433bda1.jpg https://ja.prisysbiotech.com/news/intrathecal-it-injection-a-direct-cns-deliv-17374316866888704.html 髄腔内（IT）注入：高度な治療法のための直接CNS送達ルート - 前臨床考慮事項 https://ja.prisysbiotech.com/uploads/39406/news/n202504160948404ad29.jpg https://ja.prisysbiotech.com/news/advancing-parkinson-s-disease-research-with-th-17374316694791168.html NHPモデルを使用したパーキンソン病の研究を進める https://ja.prisysbiotech.com/uploads/39406/news/n202504111626379b25c.jpg https://ja.prisysbiotech.com/news/preclinical-pk-pd-studies-nhp-models-17374316930753536.html 医薬品開発のための前臨床PK\/PD研究とNHPモデル| Prisys Biotech https://ja.prisysbiotech.com/uploads/39406/news/n2025040809451573e94.png https://ja.prisysbiotech.com/news/targeting-interleukin-31-autoimmune-disease-17299782398764032.html ターゲティングインターロイキン-31（il {-31）：自己免疫疾患医薬品開発における新しいフロンティア - 前臨床searcのPrisysバイオテクノロジーNHPモデル https://ja.prisysbiotech.com/uploads/39406/news/n202504011023488ec4a.png https://ja.prisysbiotech.com/news/nonclinical-immunotoxicity-assessment-strateg-17295703899235328.html 非臨床免疫毒性評価：戦略、重要な考慮事項、およびメソッド選択 https://img01.v15cdn.com/gallery/4x3/232.webp https://ja.prisysbiotech.com/news/microbial-testing-and-its-impact-on-nhp-17295703576404992.html 微生物検査と、前臨床DMPK研究における非ヒト霊長類へのその影響 https://ja.prisysbiotech.com/uploads/39406/news/n20250325170337bc1d3.jpg https://ja.prisysbiotech.com/news/cynomolgus-monkey-endometriosis-model-17295703782384640.html 治療研究を進めるためのCynomolgusモンキー子宮内膜症モデル https://ja.prisysbiotech.com/uploads/39406/news/n2025032013423376e5c.png https://ja.prisysbiotech.com/news/membranous-nephropathy-model-17295703597081600.html 前進膜性腎症（MN）ドラッグ開発：Prisys BiotechのCynomolgus Monkeyモデルプラットフォーム https://img01.v15cdn.com/gallery/4x3/148.webp https://ja.prisysbiotech.com/news/pharmacokinetics-of-inhaled-drugs-17295703828210688.html 吸入薬の薬物動態学：全身暴露から肺暴露へのパラダイムシフト https://ja.prisysbiotech.com/uploads/39406/news/n20250310174924e6965.png https://ja.prisysbiotech.com/news/animal-models-for-womens-health-17295703554630656.html Prisys Biotech：女性の健康療法の動物モデル https://ja.prisysbiotech.com/uploads/39406/news/n202503071009566b10b.png https://ja.prisysbiotech.com/news/world-obesity-day-nhp-metabolic-models-17295703876674560.html 世界肥満の日| PrisysバイオテクノロジーNHP代謝モデル：次世代の反肥満療法の開発のパワー https://ja.prisysbiotech.com/uploads/39406/news/n2025030417050873614.png https://ja.prisysbiotech.com/news/prisys-biotech-s-cynomolgus-monkey-psoriasis-m-17295736578450432.html Prisys BiotechのCynomolgus Monkey Faoriasisモデル：前臨床薬力学の評価評価 https://ja.prisysbiotech.com/uploads/39406/news/n202502280925537e8ce.jpg https://ja.prisysbiotech.com/news/liver-biopsy-a-crucial-technique-in-large-ani-17295703773012992.html 肝生検：新薬開発のための大型動物薬物動態（PK）研究における重要な技術 https://ja.prisysbiotech.com/uploads/39406/news/n2025022509490064708.png https://ja.prisysbiotech.com/news/integration-of-pharmacokinetics-and-pharmacody-17295703585055744.html 薬物発達における薬物動態と薬力学の統合 https://ja.prisysbiotech.com/uploads/39406/news/n2025022110272438f73.png https://ja.prisysbiotech.com/news/what-does-proof-of-concept-poc-in-drug-devel-17295703780467712.html 医薬品開発の概念実証（POC）は実際に何を検証しますか？ https://ja.prisysbiotech.com/uploads/39406/news/n20250218092412fb5f5.jpg https://ja.prisysbiotech.com/news/animal-models-challenges-and-applications-in-17295703482426368.html 動物モデル|痛みモデルの発達における課題とアプリケーション https://ja.prisysbiotech.com/uploads/39406/news/n202502141328261a025.png https://ja.prisysbiotech.com/news/nonclinical-pharmacodynamic-research-17295703753761792.html 非臨床薬力学的研究 https://ja.prisysbiotech.com/uploads/39406/news/n2025021214305230811.jpg https://ja.prisysbiotech.com/news/selecting-the-ideal-non-human-primate-for-toxi-17244147356574720.html 毒物学研究のための理想的な非人間の霊長類の選択：Cynomolgus Macaque、Rhesus Macaque、およびMarmoset https://ja.prisysbiotech.com/uploads/39406/news/n20250205142604591d8.jpg https://ja.prisysbiotech.com/news/systemic-lupus-erythematosus-sle-and-the-rol-17295703473431552.html 全身性エリテマトーデス（SLE）と治療における動物モデルの役割 https://ja.prisysbiotech.com/uploads/39406/news/n20250121104603461db.jpg https://ja.prisysbiotech.com/news/non-human-primate-model-for-rheumatoid-arthrit-17295703568294912.html 関節リウマチの非人間の霊長類モデル（RA） https://ja.prisysbiotech.com/uploads/39406/news/n20250117153412b3280.jpg https://ja.prisysbiotech.com/news/animal-brain-stereotactic-instruments-17295703480116224.html 3D座標系に基づく動物の脳定位機器 https://ja.prisysbiotech.com/uploads/39406/news/n20250115133928772c1.jpg https://ja.prisysbiotech.com/news/animal-models-for-in-vivo-testing-1-establi-17295703828227072.html 生体内試験のための動物モデル（1）：確立と分類 https://ja.prisysbiotech.com/uploads/39406/news/n20250112202508b936b.jpg https://ja.prisysbiotech.com/news/potential-routes-for-biologics-to-brain-84007095.html 生物製剤が脳に侵入する可能性のある経路を探索する https://ja.prisysbiotech.com/uploads/39406/news/n202501071034417382f.png https://ja.prisysbiotech.com/news/advancing-rheumatoid-arthritis-ra-research-w-84007096.html 非ヒト霊長類モデルを用いた関節リウマチ（RA）研究の進歩 https://ja.prisysbiotech.com/uploads/39406/news/n20250102143547c190f.jpg https://ja.prisysbiotech.com/news/animal-models-for-atopic-dermatitis-84007093.html アトピー性皮膚炎の薬効に関する動物モデルの探索 https://ja.prisysbiotech.com/uploads/39406/news/n202412301624286dab0.jpg https://ja.prisysbiotech.com/news/the-critical-role-of-animal-models-in-human-di-84007097.html 人間の病気研究における動物モデルの重要な役割 https://ja.prisysbiotech.com/uploads/39406/news/n202412271723592a539.jpg https://ja.prisysbiotech.com/news/parkin-gene-deficiency-monkey-model-reveals-ne-84007098.html パーキン遺伝子欠損サルモデルがパーキンソン病の新たなメカニズムと治療標的を明らかにする https://ja.prisysbiotech.com/uploads/39406/news/n20241224162504c3c54.jpg https://ja.prisysbiotech.com/news/nonclinical-drug-development-guide-toxicity-84007094.html 非臨床医薬品開発ガイド: 急性、亜急性、亜慢性、慢性の一般毒性研究 https://ja.prisysbiotech.com/uploads/39406/news/n20241220112548bfcff.jpg https://ja.prisysbiotech.com/news/nasal-to-brain-n2b-drug-delivery-84007103.html 革新的な鼻から脳への (N2B) 薬物送達: 血液脳関門のバイパス https://ja.prisysbiotech.com/uploads/39406/news/n202412161319158371d.jpg https://ja.prisysbiotech.com/news/minipig-as-nonclinical-large-animal-84007102.html 非臨床大型動物種としてのミニブタの機会と課題 https://ja.prisysbiotech.com/uploads/39406/news/n2024120911110171c55.jpg https://ja.prisysbiotech.com/news/drug-delivery-strategies-for-brain-diseases-82980901.html 脳疾患に対する薬物送達戦略 https://ja.prisysbiotech.com/uploads/39406/news/n202412030944155b417.jpg https://ja.prisysbiotech.com/news/real-time-intraoperative-mri-navigation-suppo-82980896.html リアルタイム術中 MRI ナビゲーション: AADC 欠損症に対する初の遺伝子治療の FDA 承認をサポート https://ja.prisysbiotech.com/uploads/39406/news/n202411280914044b8c7.jpg https://ja.prisysbiotech.com/news/ocular-toxicity-studies-of-eye-drops-drug-exp-82980892.html 点眼薬の眼毒性研究: 薬物曝露と安全性評価 https://ja.prisysbiotech.com/uploads/39406/news/n20241126163322d869c.jpg https://ja.prisysbiotech.com/news/prisys-biotech-establishes-cynomolgus-monkey-p-82653646.html Prisys Biotech、医薬品開発を加速するカニクイザル乾癬モデルを確立 https://ja.prisysbiotech.com/uploads/39406/news/n2024111910582749e02.jpg https://ja.prisysbiotech.com/news/comprehensive-non-human-primate-models-for-ren-82653641.html Prisys Biotechによる腎疾患研究用の包括的な非ヒト霊長類モデル https://ja.prisysbiotech.com/uploads/39406/news/n2024111511090891eb1.jpg https://ja.prisysbiotech.com/news/comprehensive-preclinical-safety-evaluation-of-82653643.html 非ヒト霊長類における抗体薬物複合体 (ADC) の包括的な前臨床安全性評価 https://ja.prisysbiotech.com/uploads/39406/news/n20241111141121c84f3.jpg https://ja.prisysbiotech.com/news/pharmacokinetics-evaluation-of-antibody-drug-c-82653636.html 非ヒト霊長類における抗体薬物複合体 (ADC) の薬物動態評価 https://ja.prisysbiotech.com/uploads/39406/news/n202411081401283f377.jpg https://ja.prisysbiotech.com/news/pharmacodynamics-evaluation-of-adcs-82653635.html ADC の薬力学評価 https://ja.prisysbiotech.com/uploads/39406/news/n20241106161502bd911.jpg https://ja.prisysbiotech.com/news/understanding-the-dmpk-of-adc-drugs-82653639.html ADC 薬の DMPK を理解する https://ja.prisysbiotech.com/uploads/39406/news/n20241029101148c4fbd.jpg https://ja.prisysbiotech.com/news/progress-in-the-development-of-nucleic-acid-dr-82653658.html 核酸医薬開発の進捗とPrisys Biotechの研究力 https://ja.prisysbiotech.com/uploads/39406/news/n2024101713330113621.jpg https://ja.prisysbiotech.com/news/advances-in-mrna-pulmonary-delivery-systems-an-82374895.html mRNA 肺送達システムの進歩と Prisys biotech の革新的なサービス https://ja.prisysbiotech.com/uploads/39406/news/n20241014090616a9ff8.jpg https://ja.prisysbiotech.com/news/2024-nobel-prize-in-physiology-or-medicine-82653640.html 2024 年のノーベル生理学・医学賞が、マイクロ RNA を研究したこの 2 人の科学者に授与されたのはなぜですか? https://ja.prisysbiotech.com/uploads/39406/news/n20241008113621e90e6.jpg https://ja.prisysbiotech.com/news/pharmacokinetic-pk-considerations-for-centra-82653637.html 中枢神経系（CNS）薬に関する薬物動態（PK）に関する考慮事項 https://ja.prisysbiotech.com/uploads/39406/news/n2024092913295797d3f.jpg https://ja.prisysbiotech.com/news/advancements-in-cns-research-ced-imri-79656482.html CNS研究の進歩: Prisys BiotechのMRI対応脳注入システムとCED技術 https://ja.prisysbiotech.com/uploads/39406/news/n202408062147375802b.jpg https://ja.prisysbiotech.com/news/cynomolgus-monkey-mcao-model-81120598.html カニクイザルMCAOモデルを用いた出血および凝固治療の革新の推進 https://ja.prisysbiotech.com/uploads/39406/news/n202409241700121ed48.jpg https://ja.prisysbiotech.com/news/dmpk-evaluation-of-central-nervous-system-cns-81120596.html 中枢神経系（CNS）薬のDMPK評価 https://ja.prisysbiotech.com/uploads/39406/news/n20240924110059a8fdd.png https://ja.prisysbiotech.com/news/animal-models-of-human-diseases-81120592.html ヒト疾患の動物モデル https://ja.prisysbiotech.com/uploads/39406/news/n20240920153353a85bd.png https://ja.prisysbiotech.com/news/innovations-in-pain-evaluation-ai-driven-beha-81120590.html 痛みの評価におけるイノベーション: AI を活用した行動分析 https://ja.prisysbiotech.com/uploads/39406/news/n2024091816220958caa.png https://ja.prisysbiotech.com/news/china-experimental-monkey-industry-81120594.html 中国の実験用サル産業の歴史、現状、課題、機会 https://ja.prisysbiotech.com/uploads/39406/news/n20240909130237c0dc8.jpg https://ja.prisysbiotech.com/news/human-disease-animal-models-81120602.html ヒト疾患動物モデル：生物医学研究の進歩に不可欠なツール https://ja.prisysbiotech.com/uploads/39406/news/n20240904101437e1414.jpg https://ja.prisysbiotech.com/news/the-importance-of-preclinical-pharmacodynamics-81120600.html 医薬品開発における前臨床薬力学の重要性 |プリシス・バイオテック https://ja.prisysbiotech.com/uploads/39406/news/n202408281439443e4db.jpg https://ja.prisysbiotech.com/news/intranasal-administration-in-animal-studies-81120593.html 動物実験における鼻腔内投与 https://ja.prisysbiotech.com/uploads/39406/news/n20240827104336fadf5.png https://ja.prisysbiotech.com/news/revolutionizing-cns-drug-development-prisys-b-79410698.html CNS医薬品開発に革命を起こす: PRISYS BiotechがIMRIテクノロジーを導入 https://ja.prisysbiotech.com/uploads/39406/news/n20240729151529d56e9.png https://ja.prisysbiotech.com/news/convection-enhanced-delivery-81120589.html 精密医療の進歩: Prisys Biotech による対流強化送達 (CED) テクノロジー https://ja.prisysbiotech.com/uploads/39406/news/n20240822125521f1687.jpg https://ja.prisysbiotech.com/news/cynomolgus-monkey-chronic-kidney-disease-model-81120595.html Prisys Biotech のカニクイザル慢性腎臓病 (CKD) モデル https://ja.prisysbiotech.com/uploads/39406/news/n20240820104326c1ab2.jpg https://ja.prisysbiotech.com/news/nonclinical-safety-evaluation-of-ocular-drug-d-79527632.html カニクイザルを用いた眼への薬物送達の非臨床安全性評価 https://ja.prisysbiotech.com/uploads/39406/news/n2024080116325669291.png https://ja.prisysbiotech.com/news/compartment-pk-model-81120603.html 薬物動態におけるコンパートメントモデルと非コンパートメントモデルの理解 https://ja.prisysbiotech.com/uploads/39406/news/n202408121135341dcc9.jpg https://ja.prisysbiotech.com/news/the-role-of-aav-in-gene-therapy-immune-respon-79527629.html 遺伝子治療における AAV の役割: 免疫反応と毒性 https://ja.prisysbiotech.com/uploads/39406/news/n20240801163452493e1.png https://ja.prisysbiotech.com/news/advanced-cns-delivery-techniques-in-cynomolgus-81120591.html カニクイザルにおける高度な CNS 送達技術: オリゴヌクレオチド医薬品開発の加速 https://ja.prisysbiotech.com/uploads/39406/news/n20240809165539b61ef.jpg https://ja.prisysbiotech.com/news/optimized-nonclinical-immunogenicity-evaluatio-79527625.html 最適化された非臨床免疫原性評価戦略 https://ja.prisysbiotech.com/uploads/39406/news/n2024080116353273f4d.png https://ja.prisysbiotech.com/news/reducing-the-use-of-nonhuman-primates-in-noncl-79527623.html 非臨床安全性評価における非ヒト霊長類の使用削減: FDA と業界の視点 https://ja.prisysbiotech.com/uploads/39406/news/n20240801163624dabc0.png https://ja.prisysbiotech.com/news/lcms-preclinical-bioanalysis-of-lnp-based-gene-79527656.html LNP ベースの遺伝子治療薬の LCMS 前臨床バイオ分析 https://ja.prisysbiotech.com/uploads/39406/news/n20240801181230b6a27.jpg https://ja.prisysbiotech.com/news/mrna-based-therapies-past-79527657.html MRNA ベースの治療: 過去 https://ja.prisysbiotech.com/uploads/39406/news/n2024080118112364d2d.jpg https://ja.prisysbiotech.com/news/pk-strategies-of-pdc-79527615.html ペプチド薬物複合体 (PDC) の薬物動態研究戦略 https://ja.prisysbiotech.com/uploads/39406/news/n2024080109123097cb8.png https://ja.prisysbiotech.com/news/pharmacodynamic-pd-evaluation-of-gene-therap-79527647.html 遺伝子治療の薬力学的（PD）評価 https://ja.prisysbiotech.com/uploads/39406/news/n20240801180623d1663.jpg https://ja.prisysbiotech.com/news/pharmacokinetics-and-bioanalysis-of-oligonucle-79527660.html オリゴヌクレオチド医薬品の薬物動態と生体分析-(1) https://ja.prisysbiotech.com/uploads/39406/news/n20240801180452c5c2a.jpg https://ja.prisysbiotech.com/news/pharmacokinetics-and-bioanalysis-of-oligonucle-79527649.html オリゴヌクレオチド医薬品の薬物動態と生体分析：吸収と血漿薬物動態（PK）特性 https://ja.prisysbiotech.com/uploads/39406/news/n20240801180317bc744.jpg https://ja.prisysbiotech.com/news/factors-to-consider-for-the-immunogenicity-of-79527663.html オリゴヌクレオチド医薬品の免疫原性について考慮すべき要素 https://ja.prisysbiotech.com/uploads/39406/news/n202408011801502cfb9.jpg https://ja.prisysbiotech.com/news/mrna-a-powerful-and-versatile-tool-for-fighti-79527662.html mRNA: 病気と闘うための強力で多用途なツール - Prisys-Biotech https://ja.prisysbiotech.com/uploads/39406/news/n202408011756272a013.jpg https://ja.prisysbiotech.com/news/chinese-scientists-offers-new-strategies-to-re-79527640.html 中国の科学者がパーキンソン病の主要症状を改善する新たな戦略を提案 https://ja.prisysbiotech.com/uploads/39406/news/n20240801175516ecb8a.jpg https://ja.prisysbiotech.com/news/prisys-biotechnology-novel-lipid-nanoparticle-79527631.html Prisys Biotechnology: 霊長類における mRNA 送達のための新しい脂質ナノ粒子 https://ja.prisysbiotech.com/uploads/39406/news/n2024080117542971a31.jpg https://ja.prisysbiotech.com/news/the-importance-of-translational-medicine-resea-79528393.html 基礎研究から臨床研究までのトランスレーショナル医療研究の重要性 https://ja.prisysbiotech.com/uploads/39406/news/n20240801175156b8ed0.jpg https://ja.prisysbiotech.com/news/the-main-factors-considered-in-woe-analysis-79527638.html WOE 分析で考慮される主な要素 https://ja.prisysbiotech.com/uploads/39406/news/n20240801175020842f8.jpg https://ja.prisysbiotech.com/news/how-to-deliver-biologics-to-the-brain-79528395.html 生物学的製剤を脳に届けるには？ https://ja.prisysbiotech.com/uploads/39406/news/n20240801174910a58bb.jpg https://ja.prisysbiotech.com/news/how-drugs-move-and-change-in-our-bodies-a-bri-79527636.html 薬物が体内でどのように移動し変化するか: 薬物動態学の簡単な紹介 https://ja.prisysbiotech.com/uploads/39406/news/n202408011748076fca9.jpg https://ja.prisysbiotech.com/news/how-to-develop-new-drugs-faster-and-safer-a-g-79527644.html 新薬をより早く、より安全に開発する方法: 前臨床 DMPK 研究ガイド https://ja.prisysbiotech.com/uploads/39406/news/n2024080117445005c7b.jpg https://ja.prisysbiotech.com/news/group-housing-guidelines-for-laboratory-monkey-79527635.html 実験用サルの集団飼育ガイドライン https://ja.prisysbiotech.com/uploads/39406/news/n2024080117440822f67.jpg https://ja.prisysbiotech.com/news/the-vital-role-of-experimental-monkeys-in-adva-79527651.html 科学研究の発展における実験用サルの重要な役割 https://ja.prisysbiotech.com/uploads/39406/news/n20240801174211d2a1b.jpg https://ja.prisysbiotech.com/news/understanding-macaca-fascicularis-cynomolgus-79527658.html カニクイザル（カニクイザル）の理解：主要な特徴と生物医学研究への貢献 https://ja.prisysbiotech.com/uploads/39406/news/n20240801174043f9c14.jpg https://ja.prisysbiotech.com/news/revolutionizing-metabolic-disease-treatment-a-79527643.html 代謝性疾患治療の革命: ペプチド医薬品開発の進歩と課題 https://ja.prisysbiotech.com/uploads/39406/news/n2024080117395084c9b.jpg https://ja.prisysbiotech.com/news/how-to-evaluate-the-safety-of-skin-products-be-79527626.html 臨床試験の前にスキン製品の安全性を評価するにはどうすればいいですか? https://ja.prisysbiotech.com/uploads/39406/news/n20240801173853b9e8e.jpg https://ja.prisysbiotech.com/news/the-significant-role-of-experimental-monkeys-i-79527639.html 革新的な医薬品開発における実験用サルの重要な役割：ビジネスの内部を覗く https://ja.prisysbiotech.com/uploads/39406/news/n20240801173640dbcdb.jpg https://ja.prisysbiotech.com/news/liver-toxicity-as-a-key-concern-for-sirna-drug-79527637.html siRNA 医薬品の主な懸念事項としての肝毒性: 包括的分析 標的特異性: siRNA の諸刃の剣 https://ja.prisysbiotech.com/uploads/39406/news/n20240801173252513ea.jpg https://ja.prisysbiotech.com/news/advancing-sirna-therapeutics-overcoming-chall-79527621.html SiRNA治療の進歩：医薬品開発における課題の克服 https://ja.prisysbiotech.com/uploads/39406/news/n2024080117311060b15.jpg https://ja.prisysbiotech.com/news/application-prospects-of-gene-drugs-based-on-l-79527620.html 脂質ナノ粒子に基づく遺伝子医薬品の応用展望 https://ja.prisysbiotech.com/uploads/39406/news/n20240801172808b0a45.jpg https://ja.prisysbiotech.com/news/key-points-in-designing-strategies-for-non-79527630.html 幼若動物の非臨床研究戦略を設計する際の重要なポイント https://ja.prisysbiotech.com/uploads/39406/news/n20240801172702f375a.jpg https://ja.prisysbiotech.com/news/insight-into-the-sensory-and-behavioral-traits-79527633.html 非ヒト霊長類（NHP）の感覚と行動特性に関する洞察 https://ja.prisysbiotech.com/uploads/39406/news/n2024080117261321519.jpg https://ja.prisysbiotech.com/news/nonclinical-study-evaluation-q-a-79527661.html 非臨床試験評価に関するQ&A https://ja.prisysbiotech.com/uploads/39406/news/n20240801172429e1895.jpg https://ja.prisysbiotech.com/news/significance-principles-and-requirements-of-79527665.html 安全性薬理学研究の重要性、原則、要件 https://ja.prisysbiotech.com/uploads/39406/news/n2024080117231644f61.jpg https://ja.prisysbiotech.com/news/how-to-evaluate-preclinical-pharmacological-ef-79527622.html 前臨床薬理学的有効性を評価するには？ https://ja.prisysbiotech.com/uploads/39406/news/n20240801172217a2b22.jpg https://ja.prisysbiotech.com/news/reflections-on-non-clinical-pharmacology-studi-79527645.html 非アルコール性脂肪肝炎（NASH）に対する非臨床薬理学研究と治療薬の評価に関する考察 https://ja.prisysbiotech.com/uploads/39406/news/n202408011720005c93e.jpg https://ja.prisysbiotech.com/news/advancing-cns-and-cgt-research-prisys-biotech-79527646.html CNS と CGT 研究の進歩: Prisys Biotechnologies が先導 https://ja.prisysbiotech.com/uploads/39406/news/n202408011718404c246.jpg https://ja.prisysbiotech.com/news/non-human-primate-cerebrospinal-fluid-collecti-79527650.html 非ヒト霊長類の脳脊髄液採取ガイドライン https://ja.prisysbiotech.com/uploads/39406/news/n20240801171318f7961.jpg https://ja.prisysbiotech.com/news/considerations-for-interpreting-clinical-patho-79527628.html 非ヒト霊長類 (NHP) およびイヌの臨床病理学データを解釈するための考慮事項 https://ja.prisysbiotech.com/uploads/39406/news/n2024080117122736428.jpg https://ja.prisysbiotech.com/news/integrating-cns-safety-evaluation-into-79527618.html 中枢神経系の安全性評価を一般的な毒性研究に統合 https://ja.prisysbiotech.com/uploads/39406/news/n2024080117110558056.jpg https://ja.prisysbiotech.com/news/how-to-conduct-preclinical-pharmacology-toxico-79527642.html ADC の前臨床薬理学/毒性学評価をどのように実施するのでしょうか? https://ja.prisysbiotech.com/uploads/39406/news/n20240801170828e5c98.jpg https://ja.prisysbiotech.com/news/adme-insights-for-oligonucleotide-drugs-79527652.html オリゴヌクレオチド医薬品の ADME に関する考察 (1) - 吸収、分布 https://ja.prisysbiotech.com/uploads/39406/news/n202408011705192b402.jpg https://ja.prisysbiotech.com/news/adme-insights-for-oligonucleotide-drugs-79527634.html オリゴヌクレオチド医薬品の ADME に関する考察 (2) - 代謝と排泄 https://ja.prisysbiotech.com/uploads/39406/news/n20240801164818e22a4.jpg https://ja.prisysbiotech.com/news/preclinical-animal-studies-1-animal-specie-79527619.html 前臨床動物研究（１） - 動物種 https://ja.prisysbiotech.com/uploads/39406/news/n202408011646162c426.jpg https://ja.prisysbiotech.com/news/clinical-pathology-data-interpretation-challen-79527624.html 犬および非ヒト霊長類の前臨床研究における臨床病理学データ解釈の課題と戦略 https://ja.prisysbiotech.com/uploads/39406/news/n20240801164503e9bd9.jpg https://ja.prisysbiotech.com/news/preclinical-animal-studies-2-routes-and-vo-79528398.html 前臨床動物研究（2） - 投与経路と投与量 https://ja.prisysbiotech.com/uploads/39406/news/n20240801163712d0df1.jpg https://ja.prisysbiotech.com/news/mrna-based-therapies-present-79527655.html mRNAベースの治療法：現在 https://ja.prisysbiotech.com/uploads/39406/news/n2024080118104113739.jpg https://ja.prisysbiotech.com/news/mrna-based-therapies-future-and-challenges-79527659.html mRNA ベースの治療法: 将来と課題 https://ja.prisysbiotech.com/uploads/39406/news/n2024080118092133eb2.jpg https://ja.prisysbiotech.com/news/brief-introduction-about-biological-analysis-o-79527654.html 遺伝子治療の生物学的分析についての簡単な紹介 https://ja.prisysbiotech.com/uploads/39406/news/n202408011807079dc4e.jpg https://ja.prisysbiotech.com/news/cynomolgus-monkey-in-ophthalmic-drug-research-79410700.html 眼科薬研究におけるカニクイザル https://ja.prisysbiotech.com/uploads/39406/news/n2024072509180742b12.png https://ja.prisysbiotech.com/news/prisys-nhp-models-immunology-inflammatio-79410699.html Prisys の免疫学と炎症の NHP モデルを使用したトランスレーショナルおよび交差反応性研究 https://ja.prisysbiotech.com/uploads/39406/news/n2024072212200879ff1.png https://ja.prisysbiotech.com/news/non-na-ve-nhps-in-preclinical-trials-a-cost-e-79187815.html 前臨床試験における非ナイーブ NHP: Prisys Biotech による費用対効果の高いソリューション https://ja.prisysbiotech.com/uploads/39406/news/n2024071618013071b40.png https://ja.prisysbiotech.com/news/nhp-asthma-model-79187817.html NHP喘息モデル: Prisys Biotechによる前臨床薬効研究の強化 https://ja.prisysbiotech.com/uploads/39406/news/n202407051359254acc6.png https://ja.prisysbiotech.com/news/advancing-immunology-and-inflammation-research-79187840.html カニクイザルモデルを用いた免疫学と炎症研究の進歩 - Prisys Biotechnologies https://ja.prisysbiotech.com/uploads/39406/news/n20240703110911ef80e.png https://ja.prisysbiotech.com/news/direct-delivery-of-oligonucleotide-drugs-to-th-79187813.html 中枢神経系へのオリゴヌクレオチド医薬品の直接送達と一般的な病理組織学的変化 https://ja.prisysbiotech.com/uploads/39406/news/n202406131052303d31d.png https://ja.prisysbiotech.com/news/intra-cerebrovascular-stroke-ich-model-prisys-79187816.html Prisys Biotech の脳血管内脳卒中 (ICH) モデル https://ja.prisysbiotech.com/uploads/39406/news/n20240607164926587f9.png https://ja.prisysbiotech.com/news/non-clinical-pharmacodynamics-research-an-ess-75160772.html 非臨床薬力学研究: SiRNA 医薬品の開発における重要な側面 https://ja.prisysbiotech.com/uploads/39406/news/n202402211320123fe5b.jpg https://ja.prisysbiotech.com/news/mri-guided-large-animal-central-nervous-system-77698372.html MRI 誘導による大型動物の中枢神経系の正確な位置特定と送達システムが Prisys Biotech に定着 https://ja.prisysbiotech.com/uploads/39406/news/n2024042910594482ea8.jpg https://ja.prisysbiotech.com/news/innovative-solutions-for-advancing-respiratory-77051995.html 呼吸器治療を進歩させるための革新的なソリューション https://ja.prisysbiotech.com/uploads/39406/news/n202404261311431ebfc.jpg https://ja.prisysbiotech.com/news/prisys-advancing-animal-experimentation-throu-74782916.html Prisys: カニクイザルの研究を通じて動物実験を前進させる https://ja.prisysbiotech.com/uploads/39406/news/n202402271423376ec81.png https://ja.prisysbiotech.com/news/prisys-achieves-full-accreditation-from-aaalac-76173572.html Prisys は、実験動物管理の高水準を保証するマイルストーンである AALAC International からの完全認定を取得しました。 https://img01.v15cdn.com/gallery/4x3/265.webp https://ja.prisysbiotech.com/news/elevating-nucleic-acid-therapeutics-through-cu-74654589.html Prisys Biotech 非ヒト霊長類モデルを使用した最先端の核酸治療法による核酸治療の向上 https://ja.prisysbiotech.com/uploads/39406/news/n202401261332041ba3c.jpg https://ja.prisysbiotech.com/news/revolutionizing-cns-drug-delivery-prisys-and-74123009.html 中枢神経系薬物送達の革命: Prsys とくも膜下腔内注射の約束 https://ja.prisysbiotech.com/uploads/39406/news/n20240111101138bd6a1.jpg https://ja.prisysbiotech.com/news/nonhuman-primate-study-newsletter-2024-q-75160771.html Prisys Biotech 2024 Q1 ニュースレター - 信頼できる非ヒト霊長類研究スペシャリスト https://ja.prisysbiotech.com/uploads/39406/news/n2024022009580247f09.jpg https://ja.prisysbiotech.com/news/how-ultrasound-guided-liver-biopsy-enhances-ma-73525998.html 超音波ガイド下肝生検がどのようにマカクザルベースの研究を強化するか https://ja.prisysbiotech.com/uploads/202339406/n202312211047254501881.jpg https://ja.prisysbiotech.com/news/guidelines-for-lifetime-use-of-nonhuman-primat-73525997.html 生物医学研究における非ヒト霊長類の生涯使用に関するガイドライン: Prisys バイオテクノロジーの観点 https://ja.prisysbiotech.com/uploads/39406/news/n202402271428388db72.png https://ja.prisysbiotech.com/news/non-human-primates-a-brief-introduction-to-th-73001108.html ヒト以外の霊長類: その生物学的特徴についての簡単な紹介 https://ja.prisysbiotech.com/uploads/39406/news/n202402271431193773d.png https://ja.prisysbiotech.com/news/exhibition-review-prisys-biotech-shines-at-t-72674158.html 展覧会レビュー|Prisys Biotech が米国神経科学学会年次総会 (SfN 2023) で輝く https://ja.prisysbiotech.com/uploads/202339406/n202311211050557965049.jpg https://ja.prisysbiotech.com/news/meet-prisys-biotech-at-the-society-for-neurosc-72321219.html 神経科学学会年次総会 (SfN 2023) で Prisys Biotech を紹介 https://ja.prisysbiotech.com/uploads/202339406/n202311071007243112725.jpg https://ja.prisysbiotech.com/news/world-stroke-day-focus-on-ischemic-stroke-an-72321221.html 世界脳卒中デー|虚血性脳卒中の動物モデルと薬理学に焦点を当てる https://ja.prisysbiotech.com/uploads/202339406/n202310292017544133660.jpg https://ja.prisysbiotech.com/news/prisys-biotech-invites-you-to-attend-sapa-chin-72321223.html Prisys Biotech が 2023 年の SAPA-China 年次総会にご招待します https://ja.prisysbiotech.com/uploads/202339406/n202310271316191263008.jpg https://ja.prisysbiotech.com/news/world-alzheimer-s-day-the-challenges-and-sol-72321222.html 世界アルツハイマーデー|アルツハイマー病治療薬開発の課題と解決策 https://ja.prisysbiotech.com/uploads/202339406/n202309211504565472671.jpg https://ja.prisysbiotech.com/news/prisys-biotech-s-cynomolgus-macaque-animal-mod-72321220.html Prisys Biotech のカニクイザル動物モデルが新しい抗凝固薬の開発に役立つ https://ja.prisysbiotech.com/uploads/202339406/n202309182207050266461.png https://ja.prisysbiotech.com/news/prisys-providing-high-quality-animal-experime-70941435.html Prisys: 新規抗凝固第 XI 因子抗体 BJTJ の高品質な動物実験サービスを提供-1837 https://ja.prisysbiotech.com/uploads/202339406/n202308311332528401166.jpg https://ja.prisysbiotech.com/news/method-for-establishing-a-cynomolgus-monkey-mo-70941431.html 高トリグリセリド血症のカニクイザルモデルの樹立方法とその応用 https://ja.prisysbiotech.com/uploads/202339406/n202308212156285814136.jpg https://ja.prisysbiotech.com/news/pharmacology-main-parameters-and-significance-70941436.html 薬理学: 薬物動態 (PK) の主なパラメーターと重要性 https://ja.prisysbiotech.com/uploads/202339406/n202308091145033318894.jpg https://ja.prisysbiotech.com/news/preclinical-pharmacology-evaluation-of-oncolyt-70941443.html 腫瘍溶解性ウイルス薬の前臨床薬理学的評価 https://ja.prisysbiotech.com/uploads/202339406/n202308071041585027430.jpg https://ja.prisysbiotech.com/news/0-70941434.html 低分子核酸医薬品が中枢神経系疾患の治療をどのように変革できるか: NHP 疾患モデルの大手 CRO プロバイダーである Prisys Biotechnology からの洞察 https://ja.prisysbiotech.com/uploads/202339406/n202308041018581481730.jpg https://ja.prisysbiotech.com/news/pharmacokinetics-research-strategies-and-case-70941450.html ペプチド医薬品の薬物動態、研究戦略およびケーススタディ https://ja.prisysbiotech.com/uploads/202339406/n202308031715493686411.jpg https://ja.prisysbiotech.com/news/key-research-points-of-adc-drug-pk-69653957.html ADC薬物PKの重要な研究ポイント https://ja.prisysbiotech.com/uploads/202339406/n202307302137108622628.jpg https://ja.prisysbiotech.com/news/prisys-biotechnology-a-leader-in-nhp-cns-dise-69656845.html Prisys Biotechnology: NHP CNS 疾患モデリング研究プラットフォームのリーダー https://ja.prisysbiotech.com/uploads/202339406/n202307252159358927114.jpg https://ja.prisysbiotech.com/news/how-to-lose-weight-and-control-diabetes-with-g-69309289.html GLP-1 製品で体重を減らし、糖尿病をコントロールする方法 https://ja.prisysbiotech.com/uploads/202339406/n202307162139405018976.jpg https://ja.prisysbiotech.com/news/how-china-monkey-help-to-conduct-preclinical-r-69309301.html China Monkey は前臨床研究の効率化にどのように役立っていますか? https://ja.prisysbiotech.com/uploads/39406/news/n20240227143532bd79a.png https://ja.prisysbiotech.com/news/what-is-the-efficiency-of-rnai-69309303.html RNAi の効率はどのくらいですか? https://ja.prisysbiotech.com/uploads/202339406/n202307092210201669077.jpg https://ja.prisysbiotech.com/news/large-animal-experiment-public-service-platfor-69309346.html Prisys Biotech 大動物実験公共サービス プラットフォーム: 大動物実験向けの低コストで高効率なソリューション https://ja.prisysbiotech.com/uploads/39406/news/n2024022714394317bcf.png https://ja.prisysbiotech.com/news/how-aav-gene-therapy-can-save-your-vision-the-68995851.html AAV 遺伝子治療がどのようにあなたの視力を救うことができるか: 非ヒト霊長類研究からの最新の進歩 https://ja.prisysbiotech.com/uploads/202339406/n202307022231508642715.jpg https://ja.prisysbiotech.com/news/prisys-biotech-showcases-non-human-primate-mod-68996440.html Prisys Biotech、日本毒性学会年次総会で非ヒト霊長類モデルプラットフォームを展示 https://ja.prisysbiotech.com/uploads/202339406/n202306272201578501988.jpg https://ja.prisysbiotech.com/news/the-promising-future-of-aav-gene-therapy-in-no-68996299.html ヒト以外の霊長類におけるAAV遺伝子治療の有望な未来 https://ja.prisysbiotech.com/uploads/202339406/n202306232107539553735.jpg https://ja.prisysbiotech.com/news/what-are-lipid-nanoparticles-for-gene-therapy-68997513.html 遺伝子治療用の脂質ナノ粒子とは何ですか? https://ja.prisysbiotech.com/uploads/202339406/n202306182144004132789.jpg https://ja.prisysbiotech.com/news/prisys-biotech-invites-you-to-participate-in-t-68999188.html Prisys Biotech が第 50 回日本毒性学会 (JSOT) 年次総会への参加をご案内します https://ja.prisysbiotech.com/uploads/202339406/n202306160930293342952.jpg https://ja.prisysbiotech.com/news/immunotoxicity-test-drug-safety-evaluation-pr-68996300.html 免疫毒性試験、医薬品の安全性評価 - PRISYS BIOTECH https://ja.prisysbiotech.com/uploads/202339406/n202306102132091628389.jpg https://ja.prisysbiotech.com/news/an-optimal-animal-model-of-ischemic-stroke-est-68308222.html カニクイザルにおけるデジタルサブトラクション血管造影ガイド下自己血栓によって確立された虚血性脳卒中の最適な動物モデル https://ja.prisysbiotech.com/uploads/202339406/n202306051532328723304.jpg https://ja.prisysbiotech.com/news/why-you-should-care-about-non-human-primates-68102992.html 核酸薬物送達システムの研究開発においてヒト以外の霊長類に注意を払う必要がある理由 https://ja.prisysbiotech.com/uploads/202339406/n202305282122338248983.jpg https://ja.prisysbiotech.com/news/meet-prisys-biotech-at-70th-jalas-68106064.html 第70回JALAS 2023でPrisys Biotechをご紹介します! https://ja.prisysbiotech.com/uploads/202339406/n202305232011515935612.jpg https://ja.prisysbiotech.com/news/gene-therapy-shines-with-new-approvals-for-rar-68102993.html 希少疾患に対する新たな承認で遺伝子治療が輝く https://ja.prisysbiotech.com/uploads/202339406/n202305162133347179081.jpg https://ja.prisysbiotech.com/news/revolutionizing-drug-discovery-nhp-68102991.html 創薬革命：ヒト以外の霊長類がどのようにしてsiRNAスクリーニングを最適化し、より迅速かつ効率的な結果を得るのか https://ja.prisysbiotech.com/uploads/39406/news/n20240227144111404cb.png https://ja.prisysbiotech.com/news/maximizing-sirna-pharmacology-efficiency-67241034.html ヒト以外の霊長類の研究による siRNA の薬理効率の最大化 https://ja.prisysbiotech.com/uploads/202339406/n202305022215194112233.jpg https://ja.prisysbiotech.com/news/how-nonhuman-primates-can-revolutionize-sirna-67241038.html ヒト以外の霊長類がどのように siRNA 研究に革命を起こすことができるか: 総合ガイド https://ja.prisysbiotech.com/uploads/202339406/n202304272138362221911.jpg https://ja.prisysbiotech.com/news/celebrating-world-day-for-laboratory-animals-67241040.html 実験動物の世界デーを祝って: Prisys がヒト以外の霊長類の健康増進に取り組んでいる理由 https://ja.prisysbiotech.com/uploads/202339406/n202304242046033664975.jpg https://ja.prisysbiotech.com/news/maximizing-crispr-cas9-research-efficiency-wit-67241035.html 非ヒト霊長類モデルによる CRISPR/Cas9 研究効率の最大化 https://ja.prisysbiotech.com/uploads/202339406/n202304221149520486556.jpg https://ja.prisysbiotech.com/news/unleashing-the-therapeutic-potential-67241039.html 治療の可能性を解き放つ: 核酸医薬品への投資が医学の未来である理由 https://ja.prisysbiotech.com/uploads/202339406/n202304200850383332884.jpg https://ja.prisysbiotech.com/news/unlocking-the-potential-of-nonhuman-primates-67241037.html 遺伝子治療の創薬標的発見を促進する上でヒト以外の霊長類の可能性を解き放つ https://ja.prisysbiotech.com/uploads/202339406/n202304142148160397375.jpg https://ja.prisysbiotech.com/news/world-parkinsons-disease-day-67241036.html パーキンソン病のために団結: 世界パーキンソン病デーに意識を高めるために手をつなごう https://ja.prisysbiotech.com/uploads/202339406/n202304111648126878455.jpg https://ja.prisysbiotech.com/news/nhp-effectively-in-gene-therapy-67241041.html 遺伝子治療の安全性評価にヒト以外の霊長類を効果的に使用する方法 https://ja.prisysbiotech.com/uploads/202339406/n202304102117431547381.jpg https://ja.prisysbiotech.com/news/gene-therapy-toxicology-66267819.html Nonhuam 霊長類を用いた遺伝子治療毒物学研究 https://ja.prisysbiotech.com/uploads/202339406/n202304052050241172289.jpg https://ja.prisysbiotech.com/news/dmpk-study-for-gene-therapy-66085947.html 遺伝子治療のための DMPK 研究を実施するための包括的なガイド https://ja.prisysbiotech.com/uploads/202339406/n202303292053463875854.jpg https://ja.prisysbiotech.com/news/gene-therapy-nhp-model-66085942.html 医学研究に革命を：非ヒト霊長類疾患モデルにおける遺伝子治療のブレークスルー！ https://ja.prisysbiotech.com/uploads/202339406/n202303282057377312705.jpg https://ja.prisysbiotech.com/news/top-10-popular-questions-related-to-gene-thera-66085945.html 遺伝子治療に関連するよくある質問トップ 10 https://ja.prisysbiotech.com/uploads/202339406/n202303241229248740600.jpg https://ja.prisysbiotech.com/news/prisys-biotech-non-human-primate-pharmacology-66085944.html Prisys Biotech: 遺伝子治療のための非ヒト霊長類の薬理学 https://ja.prisysbiotech.com/uploads/202339406/n202303241128310077112.jpg https://ja.prisysbiotech.com/news/supporting-women-s-health-a-look-into-endomet-66085943.html 女性の健康をサポートする: 子宮内膜症の考察 https://ja.prisysbiotech.com/uploads/202339406/n202303080917443223214.jpg https://ja.prisysbiotech.com/news/prisys-sot2023-66085939.html PRISYS と Taichu Group は 2023 年の SOT 展示会に向けて協力しています https://ja.prisysbiotech.com/uploads/202339406/n202303101009207805940.jpg https://ja.prisysbiotech.com/news/do-we-need-further-studies-for-pain-assessment-66085988.html 疼痛評価のためにさらなる研究が必要か? - NHP https://ja.prisysbiotech.com/uploads/202339406/n202303081329477852711.jpg https://ja.prisysbiotech.com/news/prisys-celebrating-world-wildlife-day-66085941.html 世界野生生物の日を祝いましょう https://ja.prisysbiotech.com/uploads/202339406/n202303031713469632535.jpg https://ja.prisysbiotech.com/news/the-construction-of-prisys-shanghai-nhp-r-d-ce-66085940.html Prisys Shanghai NHP R&D Centerが発足、中国における医薬品研究開発のマイルストーンとなる https://ja.prisysbiotech.com/uploads/202339406/n202303081340054460581.jpg https://ja.prisysbiotech.com/news/meetprisys-sot2023-66085938.html Meet Prisys @ Booth No. 1434 in The Upcoming SOT Conference | US-Roadshow https://ja.prisysbiotech.com/uploads/202339406/n202303031705254453292.jpg